BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Abbisko Therapeutics Expands Strategic Alliance with Lilly in Multi-Target Drug Discovery Deal Worth Up to $1.9 Billion

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collab...

June 25, 2026 | News

Mabwell Secures China Clinical Trial Approval for First-in-Class LILRB4/CD3 Bispecific T-Cell Engager in Blood Cancers

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical P...

June 25, 2026 | News

WuXi Biologics Achieves First GMP Production at Shanghai MFG17, Expanding Global Biologics Manufacturing Capacity

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance f...

June 25, 2026 | News

China Approves World's First CAR-T Therapy for Solid Tumours

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by...

June 24, 2026 | News

Avance Clinical Expands APAC And China Operations To Accelerate Global Biotech Trials

Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, announced a significant expansion of its Asia Pacif...

June 22, 2026 | News

Qihan Biotech’s Universal CAR-T Therapy QT-019B Secures FDA’s ‘Triple Crown’ of Expedited Designations

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to c...

June 18, 2026 | News

Dimerix Signs Up to AU$481 Million Licensing Deal with Everest Medicines to Advance Phase 3 Kidney Disease Therapy Across Asia

Dimerix Limited (ASX: DXB), a biopharmaceutical company developing innovative therapies for rare inflammatory diseases, has entered into an exclusive licen...

June 17, 2026 | News

Harbour BioMed's Antibody Innovation Prevails in Major Patent Clash with Amgen

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's g...

June 16, 2026 | News

QingSong Health and Basel Medical Group Forge Strategic Alliance to Advance AI Healthcare in Southeast Asia

QingSong Health Corp (2661.HK) and Basel Medical Group Ltd announced the signing of a Memorandum of Strategic Cooperation. The two parties i...

June 15, 2026 | News

Simcere and Stanford Medicine Partner to Advance First-in-Class Therapy for Idiopathic Pulmonary Fibrosis

Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory stu...

June 15, 2026 | News

Windward Bio Doses First Patients in Phase II COPD Trial of SKB378/WIN378

COPD study initiation expands SKB378/WIN378 development into a second major respiratory disease SKB378/WIN378 is currently being evaluated in the Phase ...

June 11, 2026 | News

Formation Bio Doses First Participant in Phase I Trial of Lynk’s CNS-Penetrant TYK2 Inhibitor

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseas...

June 12, 2026 | News

China Approves First-in-Human Trial of Antengene’s ATG-201 for Autoimmune Diseases

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, d...

June 12, 2026 | News

XtalPi Lands $400M+ AI-Driven Drug Discovery Partnership for Metabolic GPCR Target

XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, announced a strategic partnership with a pro...

June 12, 2026 | News

Stay Connected